Understanding the Potential of mRNA as Biomarker to Revolutionize Diagnosis of Colorectal Cancer.

IF 1.7 Q3 PHARMACOLOGY & PHARMACY

Drug Research Pub Date : 2024-03-01 Epub Date: 2024-02-13 DOI:10.1055/a-2244-6572

Rina Das, Dinesh Kumar Mehta, Nidhi Gupta

{"title":"Understanding the Potential of mRNA as Biomarker to Revolutionize Diagnosis of Colorectal Cancer.","authors":"Rina Das, Dinesh Kumar Mehta, Nidhi Gupta","doi":"10.1055/a-2244-6572","DOIUrl":null,"url":null,"abstract":"<p><p>MicroRNA as potential biomarker for early diagnosis, differentiating various stages, interpreting the success of postoperative curative surgery and predicting early relapse of Colorectal cancer.In the realm of medical research, the quest to find effective biomarkers for various diseases has always been a top priority. Colorectal cancer (CRC), one of the leading causes of cancer-related deaths worldwide, is no exception. The emergence of microRNA (mRNA) as a potential biomarker for CRC has sparked immense interest among scientists and clinicians alike. mRNA, a molecule responsible for translating genetic information into functional proteins, presents a promising avenue for early detection and personalized treatment of this deadly disease. By analyzing the specific patterns and levels of mRNA expression in CRC cells, researchers have the ability to identify signatures that can aid in accurate diagnosis, predict patient prognosis, and even guide targeted therapies. This breakthrough in molecular biology not only enhances our understanding of CRC but also holds the potential to revolutionize the field of cancer diagnostics and treatment. In this article, we will delve deeper into the potential of mRNA as a biomarker for CRC, exploring its benefits and challenges in the field of cancer research.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"102-112"},"PeriodicalIF":1.7000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2244-6572","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

MicroRNA as potential biomarker for early diagnosis, differentiating various stages, interpreting the success of postoperative curative surgery and predicting early relapse of Colorectal cancer.In the realm of medical research, the quest to find effective biomarkers for various diseases has always been a top priority. Colorectal cancer (CRC), one of the leading causes of cancer-related deaths worldwide, is no exception. The emergence of microRNA (mRNA) as a potential biomarker for CRC has sparked immense interest among scientists and clinicians alike. mRNA, a molecule responsible for translating genetic information into functional proteins, presents a promising avenue for early detection and personalized treatment of this deadly disease. By analyzing the specific patterns and levels of mRNA expression in CRC cells, researchers have the ability to identify signatures that can aid in accurate diagnosis, predict patient prognosis, and even guide targeted therapies. This breakthrough in molecular biology not only enhances our understanding of CRC but also holds the potential to revolutionize the field of cancer diagnostics and treatment. In this article, we will delve deeper into the potential of mRNA as a biomarker for CRC, exploring its benefits and challenges in the field of cancer research.

查看原文本刊更多论文

了解 mRNA 作为生物标记物的潜力，彻底改变结直肠癌诊断。

微RNA作为潜在的生物标志物，可用于结直肠癌的早期诊断、区分不同阶段、解读术后根治手术的成功率以及预测早期复发。在医学研究领域，寻找各种疾病的有效生物标志物一直是重中之重。在医学研究领域，寻找各种疾病的有效生物标记物一直是重中之重，结直肠癌（CRC）作为全球癌症相关死亡的主要原因之一也不例外。mRNA是一种负责将遗传信息转化为功能性蛋白质的分子，它为这种致命疾病的早期检测和个性化治疗提供了一条很有前景的途径。通过分析 CRC 细胞中 mRNA 表达的特定模式和水平，研究人员有能力找出有助于准确诊断、预测患者预后甚至指导靶向治疗的特征。分子生物学领域的这一突破不仅增进了我们对 CRC 的了解，还有可能彻底改变癌症诊断和治疗领域。在本文中，我们将深入探讨 mRNA 作为 CRC 生物标记物的潜力，探讨它在癌症研究领域的优势和挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Research PHARMACOLOGY & PHARMACY-

CiteScore

3.50

自引率

0.00%

发文量

期刊介绍： Drug Research (formerly Arzneimittelforschung) is an international peer-reviewed journal with expedited processing times presenting the very latest research results related to novel and established drug molecules and the evaluation of new drug development. A key focus of the publication is translational medicine and the application of biological discoveries in the development of drugs for use in the clinical environment. Articles and experimental data from across the field of drug research address not only the issue of drug discovery, but also the mathematical and statistical methods for evaluating results from industrial investigations and clinical trials. Publishing twelve times a year, Drug Research includes original research articles as well as reviews, commentaries and short communications in the following areas: analytics applied to clinical trials chemistry and biochemistry clinical and experimental pharmacology drug interactions efficacy testing pharmacodynamics pharmacokinetics teratology toxicology.